Allahabad High Court asks Centre to fund treatment of 3 children with rare disorder
Source Entity
Ashish Shaji
The Allahabad High Court has directed the Centre to provide financial aid for three children suffering from the rare genetic disorder Mucopolysaccharidosis Type-I. The court emphasized that the exorbitant costs of such treatments necessitate state intervention to ensure equitable access to healthcare.
Judicial Intervention in Rare Disease Healthcare
The Allahabad High Court recently issued a significant directive concerning the intersection of fundamental rights and healthcare accessibility. By ordering the Centre to consider financial assistance for three children diagnosed with Mucopolysaccharidosis Type-I (MPS-I), specifically the Hurler-Scheie phenotype, the court has underscored the state's responsibility to protect vulnerable citizens facing catastrophic medical costs. The bench, comprised of Justices Alok Mathur and Amitabh Kumar Rai, recognized that for many families, the financial burden of managing rare genetic conditions is simply insurmountable.
Understanding the Medical Challenge
Mucopolysaccharidosis Type-I (MPS-I) is a rare, life-altering genetic disorder characterized by the body's inability to produce a necessary enzyme to break down long chains of sugar molecules. The Hurler-Scheie phenotype represents a spectrum of this condition, requiring specialized, long-term medical management. With treatment costs estimated at approximately Rs 72 lakh per year, the economic reality of the disease often precludes families from seeking life-saving interventions without external support.
The Role of SGPGI in Specialized Care
The court’s order includes the immediate admission of these three children to the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI) in Lucknow. This referral is critical, as SGPGI serves as a center of excellence for tertiary care. By mandating evaluation at this institution, the court ensures that the medical necessity is verified by top-tier specialists, providing a rigorous clinical foundation for the subsequent funding requests made to the central government.
Broader Implications for Rare Disease Policy
The observations made by Justices Mathur and Kumar Rai touch upon the broader necessity of a state-funded safety net for rare diseases. In cases where treatment costs are “so exorbitant as to be beyond the reach of ordinary citizens,” the judiciary is increasingly stepping in to interpret the right to life as encompassing the right to essential, life-saving medical care. This case serves as a benchmark for how courts may compel the state to bridge the gap between high-cost medical innovation and the impoverished patient.
Future Trends in Public Health Law
Looking forward, this ruling may influence how rare disease policies are drafted at the national level. As diagnostic capabilities improve, the number of identified cases of rare genetic disorders is likely to rise, placing further pressure on public health funding models. The Allahabad High Court’s proactive stance suggests a growing judicial expectation that the government must develop more sustainable, institutionalized financial mechanisms for rare disease management, rather than relying on ad-hoc petitions and individual court orders.
Conclusion
Ultimately, this directive represents a humanitarian victory for the families involved and a legal precedent for the right to health in India. By acknowledging the economic disparity inherent in treating rare genetic disorders, the court has highlighted a critical gap in the existing healthcare framework. The ongoing monitoring of this case will be vital in determining if the Centre can establish a viable path for funding these essential treatments, potentially setting a standard for future medical welfare policies.